Zealand Pharma — Earnings Release 2016

Feb 8, 2017

ZEAL&

Company announcement – No. 3 / 2017

Zealand reports Q4 2016 Lyxumia® royalty revenue

Zealand receives royalty revenue of DKK 5.3 million / €0.7 million in Q4 2016 (and DKK 24.4 million / €3.3 million in full year 2016) from sales of Lyxumia® by Sanofi outside the United States.

Copenhagen, 8 February 2017 - Zealand Pharma (Zealand) reports royalty revenue from Sanofi's sales of Lyxumia® (lixisenatide) outside the United States of DKK 5.3 million / €0.7 million for Q4 2016. Zealand's annual royalty revenue in respect of Lyxumia® amounted to DKK 24.3 million / €3.3 million in 2016.

Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand. Zealand licensed the global development and commercialization rights to lixisenatide to Sanofi. Lixisenatide is marketed under the brand name Lyxumia® in over 45 countries and was launched in the United States under the brand name Adlyxin™ in January 2017.

Sanofi has also developed a combination of lixisenatide and insulin glargine 100 units/mL (Lantus®), which was approved by: (i) the US Food and Drug Administration in November 2017 and is being marketed under the brand name Soliqua™ 100/33 in the United States and (ii) the European Medicines Agency in January 2017 and is expected to be marketed in Europe under the brand name Suliqua™¹.

Since January 2017, Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) has been available by prescription in US pharmacies. Soliqua™ 100/33 is approved in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide alone. Sanofi has announced that it expects to launch marketing of Suliqua™ in certain EU countries in the second quarter of 2017.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, email: mabl@zealandpharma.com

Zealand Pharma A/S

---

Zealand Pharma A/S
2/2

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates that primarily target specialty diseases with significant unmet needs.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin™ in the US and Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua™ 100/33 in the US and has been approved as Suliqua™ in Europe.

Zealand's pipeline includes: dasiglucagon (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (phase II); glepaglutide (ZP1848) for short bowel syndrome (phase II); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (phase II) and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

• Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).